Nestle Carefully Targets Weight-Loss Drug Users With New Food Line
Nestle Carefully Targets Weight-Loss Drug Users With New Food Line
Last month, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management.
上個月，雀巢（場外交易：NSRGF）（場外交易：NSRGY）推出了Vital Pursuit，這是一系列旨在補充GLP-1減肥藥物並幫助專注於體重管理的消費者的食物。
The European food giant said the company will not mention the weight loss drugs on the packaging.
這家歐洲食品巨頭表示，公司不會在包裝上提到減肥藥品。
Tom Moe, President of Meals at Nestle USA, stated that the company's Vital Pursuit line would be marketed primarily through social media to avoid regulatory issues.
雀巢美國餐食總裁湯姆・莫（Tom Moe）表示，該公司的Vital Pursuit系列將主要通過社交媒體進行營銷，以避免監管問題。
"We won't directly make the connection (to the drugs) on the food package," Moe emphasized in a Reuters report.
莫在路透社的一篇報道中強調，“我們不會在食品包裝上直接與（藥物）聯繫起來。”
This decision highlights the regulatory uncertainties that global food companies face when targeting the growing market of people using appetite-suppressing medications, such as Novo Nordisk A/S's (NYSE:NVS) Wegvoy and Eli Lilly And Co's (NYSE:LLY) Zepbound.
這一決定凸顯了全球食品公司在針對使用食慾抑制藥物的不斷增長的市場時面臨的監管不確定性，如Novo Nordisk A/S（紐交所：NVS）的Wegovy和Eli Lilly And Co的（紐交所：LLY）Zepbound。
The medications, known as GLP-1 agonists, have impacted snack-makers and fast-food chains as consumers reduce their food intake.
這些被稱爲GLP-1激動劑的藥物已經影響到零食製造商和快餐連鎖店，因爲消費者減少了食物攝入量。
Reuters report adds that Nestle's Vital Pursuit products will compete with brands that make specific claims for people who are on these medications.
路透社的報道補充說，雀巢的Vital Pursuit產品將與聲稱適合使用這些藥物的品牌競爭。
For example, Biocare, a drink priced at $4.50 per serving, claims to alleviate side effects like nausea for users of semaglutide, the active ingredient in Wegovy and Ozempic.
例如，一種名爲Biocare的飲料，每份售價$4.50，聲稱緩解使用Wegovy和Ozempic的有機磷模擬劑（semaglutid的活性成分）的用戶的噁心等副作用。
Referencing weight-loss drugs on Vital Pursuit packaging could lead to regulatory scrutiny. "We're not a medication, we're a food product," Moe noted. Mentioning medications could imply that the food treats or prevents disease, a claim only FDA-approved products can make.
在Vital Pursuit包裝上提到減肥藥品可能會引起監管的關注。 “我們不是藥品，而是食品產品，”莫指出。提及藥物可能意味着該食品治療或預防疾病，這是隻有FDA批准的產品才能宣稱的。
The report further quoted Lauren Handel, an attorney specializing in food regulations, who advised that the safest approach is to avoid mentioning any drugs. "It's a tricky area where you'd want to be careful about what you say," she said, noting that labeling products as "suitable for people on a diet" may comply with regulations.
這份報告進一步引用了專門從事食品監管的律師Lauren Handel的話，他建議最安全的做法是避免提及任何藥物。 “這是一個棘手的領域，你需要小心你說的話，”她說，稱將產品標記爲“適合節食的人”可能符合法規。
Nestle has not disclosed whether it will refer to the drugs in advertisements.
雀巢沒有透露是否在廣告中提到這些藥物。
In contrast, Herbalife Ltd (NYSE:HLF) has taken a direct approach, promoting its GLP-1 Companion Pack on Facebook to support the nutritional needs of people using GLP-1 weight-loss drugs.
相比之下，康寶萊（紐交所：HLF）採取了直接的方式，在Facebook上推廣其GLP-1 Companion Pack，以支持正在使用GLP-1減肥藥物的人們的營養需求。
Frank Lamberti, Herbalife's Chief Commercial Officer, said the company avoids brand names like Ozempic to avoid alienating users of other drugs such as Eli Lilly's Mounjaro and Zepbound.
康寶萊的首席商務官Frank Lamberti說，該公司避免使用Ozempic等品牌名稱，以避免疏遠其他藥物的用戶，如Eli Lilly的Mounjaro和Zepbound。
Other companies, including Coca-Cola Company (NYSE:KO) and yogurt-maker Danone (OTC:DANOY), are positioning their products as suitable for weight-loss medications due to their low sugar or high protein content. Conagra Brands, Inc. (NYSE:CAG), maker of Healthy Choice meals, will also avoid drug names on packaging.
其他公司，包括可口可樂公司（紐交所：KO）和酸奶製造商丹尼（場外交易：DANOY），將其產品定位爲適用於減肥藥物，因爲其低糖或高蛋白質含量。康亞加品牌公司（紐交所：CAG）的Healthy Choice餐食製造商也將避免在包裝上使用藥名。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明本內容部分由人工智能工具生成，並經Benzinga編輯審核和發佈。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。